This editorial refers to 'Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry' † , by H.B. Ribeiro et al., on page 687.
Transcatheter implantation of a prosthesis in a degenerated aortic bioprosthesis [valve-in-valve (ViV)] was initially an off-label application of transcatheter aortic valve implantation (TAVI), which rapidly appeared of interest since patients with degenerated bioprostheses are likely to be at higher risk for surgery than those with native aortic stenosis. Transcatheter ViV is now recognized as an option for patients at high risk for surgery in American and European guidelines. 1, 2 Transcatheter aortic ViV accounted for 3 .3% of all TAVI procedures between 2012 and 2015 in the Society of Thoracic Surgeons/ American College of Cardiology (ACC) Transcatheter Valve Therapy Registry, and the rate of ViV increased from 1.7% between 2010 and 2012 to 4 .4% between 2013 and 2015 in the FRANCE-2 and FRANCE TAVI registries. 3, 4 The number of ViV procedures is likely to increase in the future given the growing use of bioprostheses over the last decades, in particular in younger patients. 5, 6 The study by Ribeiro et al. published in this issue of the journal draws attention to coronary obstruction in the particular case of transcatheter aortic ViV procedures. 7 The rationale for studying this rare but severe complication in patients undergoing ViV was justified by a previous study showing higher rates of coronary obstruction after transcatheter ViV than after TAVI for native aortic stenosis. 8 A strength of this study is that it is based on the largest experience in ViV from a multicentre international registry totalling 1612 procedures. The 2.5% rate of coronary obstruction after ViV found in the previous study was based on only three cases of coronary obstruction out of 121 patients. The 2.3% rate reported in the present study is consistent but more robust since it is calculated from 37 cases of coronary obstruction occurring in 1612 patients who underwent ViV procedures. The true rate of coronary obstruction is probably higher due to the possibility of clinically silent cases, in particular in patients with previous coronary artery bypass grafting. In addition to more accurate estimations, the study of a larger number of cases allows for the search of predictive factors. The only clinical factor significantly associated with the risk of coronary obstruction was the presence of a stentless prosthesis or a stented prosthesis with externally mounted leaflets. These findings are consistent with smaller series and can be interpreted by a higher risk of interaction between the bioprosthetic cusps and coronary ostia, most often involving the left coronary artery. Conversely, the 0.7% rate of coronary obstruction reported after ViV in patients who have a stented prosthesis with externally mounted leaflets is not higher than after TAVI in patients with native aortic stenosis. 8 This is of importance since stented prostheses with internally mounted leaflets have been widely used. With regards to the prosthesis implanted during transcatheter ViV, there was no significant difference in coronary obstruction rate between balloon-expandable and selfexpanding prostheses ( Figure 1) . However, coronary obstruction may occur later with self-expanding than balloon-expandable prostheses. This finding raises questions regarding the mechanism of delayed obstruction and optimal patient monitoring. Another predictive factor of coronary obstruction is related to imaging. The authors describe a new measurement obtained from computed tomography (CT) scan, the virtual transcatheter valve to coronary ostium (VTC) distance, which appears to be strongly associated with the risk of coronary obstruction. The value of VTC distance to predict coronary obstruction should, however, be interpreted with caution. First, analysis of CT scans was performed in a subset of 20 of the 37 patients of the whole population. Secondly, the suggested cut-off value of VTC distance to predict coronary obstruction raises the question of its reproducibility when analysed outside a central core lab. Thirdly, multivariable analysis of CT data in this paper is a case-control study with potential inherent bias. 
The value of VTC distance in routine practice needs to be confirmed by prospective external validation. The impact of the VTC distance is a further illustration of the value of multimodality imaging in the evaluation of potential candidates for TAVI.
The present study further confirms the particularly poor prognosis of coronary obstruction. Overall 30-day mortality was 49%, although coronary revascularization was attempted in 30 of 36 patients. Percutaneous coronary intervention (PCI) was attempted in 28 patients but was successful in only 18 patients, and 30-day mortality reached 80% after unsuccessful PCI. Most PCI failures were the consequence of canulation or wire crossing failure. Although these procedures were performed in experienced centres, the presence of a TAVI prosthesis makes PCI more complex and potentially less successful, in particular for emergency procedures. These findings justify the performance of transcatheter ViV in centres with appropriate resources for haemodynamic support and immediate conversion to open-heart surgery. The importance of emergency coronary revascularization is attested to by the fact that no death occurred after hospital discharge and that survivors had favourable 1-year outcome when considering functional status and left ventricular function.
The study by Ribeiro et al. may already have implications in clinical practice with regard to patient selection and the different steps of management. In patients candidates for surgical aortic valve replacement, the potential interest in using a stentless prosthesis or a stented prosthesis with externally mounted leaflets may be reconsidered in the light of the risk of coronary obstruction in the perspective of subsequent ViV. Patients with a stentless prosthesis or a stented prosthesis with externally mounted leaflets should not be systematically denied transcatheter ViV, but the higher risk of coronary obstruction may lead to considering even more the option of redo surgery. The risk of coronary obstruction should be included among the factors taken into account in risk assessment performed by the Heart Team. The same consideration may also apply to patients with low values of VTC distance. When an indication for ViV is chosen by the Heart Team in a patient at high risk of coronary obstruction, the authors suggest that additional security measures can be used during the procedure, such as a protection of the left main with a guidewire, possibly with an undeployed stent to speed up diagnosis and treatment in case of coronary obstruction. The use of repositionable and retrievable devices may also be an attractive alternative in patients at high risk of coronary obstruction. After the procedure, particular awareness is needed regarding any haemodynamic instability leading to prompt ECG and coronary angiography. However, surprisingly, only 53% of the patients with coronary obstruction had ECG changes in this series, which may delay the diagnosis.
Beyond the impact on individual patient selection, the risk of coronary obstruction after transcatheter aortic ViV has broader implications for the treatment of valvular diseases. The possibility of performing ViV is frequently considered as an additional incentive to favour the implantation of surgical bioprosthesis in younger patients. In the recent update of the American Heart Association/ACC guidelines, the age under which a mechanical prosthesis is favoured in the aortic position has been lowered from 60 to 50 years. 2 The implantation of bioprostheses in patients who have a longer life expectancy will increase the number of patients with degenerated bioprostheses since degeneration occurs in approximately half of patients after 20 years. 9 The experience of transcatheter ViV remains, however, limited, in particular with regards to long-term follow-up. Small aortic bioprostheses are associated with lower survival, illustrating the consequence of patient-prosthesis mismatch since the TAVI prosthesis is smaller than the original bioprosthesis. 10, 11 The risk of coronary obstruction is an additional source of concern. It cannot be expected to be lower in patients at lower risk of surgery since there was no association between patient characteristics and the risk of coronary obstruction in the present study. Finally, results from registries and trials concerning TAVI for native aortic stenosis should not be extrapolated to transcatheter ViV. This justifies an additional word of caution when considering indications for ViV. 1, 2, 12 Remaining uncertainties and concerns show that it is too early to consider transcatheter ViV as the routine treatment of degenerated aortic bioprostheses and that redo surgery remains the reference treatment in patients who are not at high risk for surgery. 1, 2 Finally, the study by Ribeiro et al. is a further proof of the importance of large multicentre registries which are the only means to assess accurately the rates of rare but severe complications of interventional procedures, their predictive factors, and outcome. Although considerable information has already been gathered in the field of TAVI, continuing data collection in registries remains necessary to refine indications in specific clinical presentations. These findings also reinforce the importance of the evaluation by the Heart Team and the performance of these procedures in medico-surgical centres. 
